MA30988B1 - Composes destines a inhiber la progression mitotique - Google Patents

Composes destines a inhiber la progression mitotique

Info

Publication number
MA30988B1
MA30988B1 MA31985A MA31985A MA30988B1 MA 30988 B1 MA30988 B1 MA 30988B1 MA 31985 A MA31985 A MA 31985A MA 31985 A MA31985 A MA 31985A MA 30988 B1 MA30988 B1 MA 30988B1
Authority
MA
Morocco
Prior art keywords
compounds
mitotic progression
inhibiting mitotic
cancer
treatment
Prior art date
Application number
MA31985A
Other languages
English (en)
Inventor
Christopher F Claiborne
Todd B Sells
Stephen G Stroud
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39315133&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30988(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MA30988B1 publication Critical patent/MA30988B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DES COMPOSÉS REPRÉSENTÉS PAR LA FORMULE GÉNÉRALE (I), AINSI QUE DES PROCÉDÉS DESTINÉS AU TRAITEMENT DU CANCER. L'INVENTION CONCERNE PLUS PARTICULIÈREMENT DE PUISSANTS INHIBITEURS DE LA KINASE AURORA A, DES COMPOSITIONS PHARMACEUTIQUES COMPRENANT LES COMPOSÉS, AINSI QUE DES PROCÉDÉS D'UTILISATION DE CES COMPOSÉS POUR LE TRAITEMENT DU CANCER.
MA31985A 2006-11-16 2009-06-12 Composes destines a inhiber la progression mitotique MA30988B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85934006P 2006-11-16 2006-11-16

Publications (1)

Publication Number Publication Date
MA30988B1 true MA30988B1 (fr) 2009-12-01

Family

ID=39315133

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31985A MA30988B1 (fr) 2006-11-16 2009-06-12 Composes destines a inhiber la progression mitotique

Country Status (34)

Country Link
US (7) US8026246B2 (fr)
EP (4) EP2086981B1 (fr)
JP (3) JP5102839B2 (fr)
KR (2) KR101110458B1 (fr)
CN (2) CN103483343B (fr)
AR (1) AR064246A1 (fr)
AT (1) ATE556076T1 (fr)
AU (1) AU2007322046B2 (fr)
BR (1) BRPI0718803B8 (fr)
CA (1) CA2669680C (fr)
CL (1) CL2007003244A1 (fr)
CR (3) CR10782A (fr)
CY (1) CY1112828T1 (fr)
DK (2) DK2086981T3 (fr)
EA (1) EA015779B1 (fr)
ES (3) ES2537451T3 (fr)
GE (1) GEP20125459B (fr)
HR (2) HRP20120490T1 (fr)
IL (1) IL198690A0 (fr)
MA (1) MA30988B1 (fr)
MX (3) MX2009004670A (fr)
MY (1) MY153243A (fr)
NO (1) NO343338B1 (fr)
NZ (3) NZ611898A (fr)
PH (1) PH12012502057B1 (fr)
PL (2) PL2086981T3 (fr)
PT (2) PT2497772E (fr)
RS (2) RS53788B1 (fr)
SG (2) SG10201503350TA (fr)
SI (2) SI2086981T1 (fr)
TW (1) TWI401255B (fr)
UA (1) UA94129C2 (fr)
WO (1) WO2008063525A1 (fr)
ZA (1) ZA200903279B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE381566T1 (de) 2004-05-14 2008-01-15 Millennium Pharm Inc Verbindungen und verfahren zur inhibierung der mitotischen progression durch hemmung von aurorakinase
CL2007003244A1 (es) * 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
TW201026703A (en) * 2008-12-05 2010-07-16 Millennium Pharm Inc Thiolactams and uses thereof
ES2468391T3 (es) * 2008-12-22 2014-06-16 Millennium Pharmaceuticals, Inc. Combinación de inhibidores de cinasas Aurora y anticuerpos anti-CD20
JO3635B1 (ar) * 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) * 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
JP2013520424A (ja) * 2010-02-19 2013-06-06 ミレニアム ファーマシューティカルズ， インコーポレイテッド ナトリウム４−｛［９−クロロ−７−（２−フルオロ−６−メトキシフェニル）−５Ｈ−ピリミド［５，４−ｄ］［２］ベンゾアゼピン−２−イル］アミノ｝−２−メトキシベンゾエートの結晶形
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
ES2526671T3 (es) * 2010-06-22 2015-01-14 Glaxosmithkline Llc Compuestos de benzotriazoldiazepina inhibidores de bromodominios
AR086656A1 (es) * 2011-06-03 2014-01-15 Millennium Pharm Inc Combinacion de inhibidores de mek e inhibidores selectivos de la quinasa aurora a
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
CN103772391A (zh) * 2012-10-23 2014-05-07 杨子娇 一类治疗房角狭窄的化合物及其用途
WO2014153509A1 (fr) 2013-03-22 2014-09-25 Millennium Pharmaceuticals, Inc. Combinaison d'inhibiteurs catalytiques de mtorc1/2 et inhibiteurs sélectifs de la kinase aurora a
US10335494B2 (en) 2013-12-06 2019-07-02 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-CD30 antibodies
WO2016106357A1 (fr) * 2014-12-23 2016-06-30 Millennnium Pharmaceuticals, Inc. Combinaison d'inhibiteurs de raf et d'inhibiteurs de kinases aurora
WO2017015316A1 (fr) 2015-07-21 2017-01-26 Millennium Pharmaceuticals, Inc. Administration d'inhibiteur de kinase aurora et d'agents chimiothérapeutiques
JP6955485B2 (ja) 2015-09-09 2021-10-27 アイカーン スクール オブ メディスン アット マウント サイナイＩｃａｈｎ Ｓｃｈｏｏｌ ｏｆ Ｍｅｄｉｃｉｎｅ ａｔ Ｍｔ． Ｓｉｎａｉ 抗がん剤としての複素環式の限定された三環系スルホンアミド
EP3347350A1 (fr) 2015-09-09 2018-07-18 Icahn School of Medicine at Mount Sinai Sulfonamides hétérocycliques tricycliques contraints en tant qu'agents anti-cancéreux
JP6591036B2 (ja) 2016-02-26 2019-10-16 公益財団法人がん研究会 Ｈｐ１の機能に着目した抗癌剤のスクリーニング方法及び評価系
ES3057783T3 (en) 2016-03-15 2026-03-04 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
JP6188986B1 (ja) * 2017-03-23 2017-08-30 株式会社ノエビア 時計遺伝子発現量調整剤及びエラスチン産生促進剤
US11874276B2 (en) 2018-04-05 2024-01-16 Dana-Farber Cancer Institute, Inc. STING levels as a biomarker for cancer immunotherapy
WO2020049208A1 (fr) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa comme cible pour traiter, prévenir ou soigner une infection par vih ou le sida
WO2021041532A1 (fr) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Utilisation d'héparine pour favoriser la signalisation de l'interféron de type 1
EP4504710A1 (fr) 2022-04-07 2025-02-12 Eli Lilly and Company Procédé de fabrication d'un inhibiteur de kras g12c
EP4504209A1 (fr) 2022-04-08 2025-02-12 Eli Lilly and Company Méthode de traitement comprenant des inhibiteurs de kras g12c et des inhibiteurs d'aurora a
EP4547251A1 (fr) 2022-06-30 2025-05-07 Eli Lilly and Company Inhibiteur de kras g12c pour le traitement du cancer
WO2025075211A1 (fr) 2023-10-03 2025-04-10 Takeda Pharmaceutical Company Limited Alisertib et paclitaxel pour le traitement du cancer du poumon à petites cellules
WO2025245045A1 (fr) 2024-05-21 2025-11-27 The Regents Of The University Of California Méthodes de traitement du cancer du poumon

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099012A (en) 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
US4481142A (en) 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
FR2450833A1 (fr) 1979-02-07 1980-10-03 Hoffmann La Roche Derives de benzazepine
US4469633A (en) 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
EP0273697A3 (fr) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-Benzazépines à cycles hétérocycliques de 5 et 6 côtés
US5166151A (en) 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5210082A (en) 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
NZ330973A (en) * 1996-03-08 2000-03-27 Zeneca Ltd Azolobenzazepine derivatives as neurologically active agents
AU5330698A (en) * 1996-12-23 1998-07-17 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
IL135303A0 (en) * 1997-09-29 2001-05-20 Meiji Seika Kaisha Tricyclic triazolobenzazepine derivatives, process for producing the same and antiallergic agents
US6277844B1 (en) 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
AU4841700A (en) 1999-05-12 2000-11-21 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
AU1651201A (en) 1999-12-06 2001-06-18 Ajinomoto Co., Inc. Amidinophenylpyruvic acid derivative
EP1345925B1 (fr) 2000-12-21 2006-05-17 Vertex Pharmaceuticals Incorporated Composes de pyrazole presentant une grande utilite comme inhibiteurs de proteine kinase
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
DE10135457A1 (de) * 2001-07-20 2003-02-06 Adc Automotive Dist Control Optische Sensoranordnung
WO2003013545A1 (fr) 2001-08-09 2003-02-20 Actelion Pharmaceuticals Ltd Heterocycles a fusion benzo utilises comme antagonistes vis-a-vis de l'endotheline
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
ATE381566T1 (de) * 2004-05-14 2008-01-15 Millennium Pharm Inc Verbindungen und verfahren zur inhibierung der mitotischen progression durch hemmung von aurorakinase
US8153630B2 (en) 2004-11-17 2012-04-10 Miikana Therapeutics, Inc. Kinase inhibitors
WO2006070198A1 (fr) 2004-12-30 2006-07-06 Astex Therapeutics Limited Derives pyrazoliques modulant l'activite des kinases cdk, gsk et aurora
ES2408318T3 (es) 2005-12-23 2013-06-20 Glaxosmithkline Llc Inhibidores de azaindol de las cinasas Aurora
WO2008021038A2 (fr) 2006-08-09 2008-02-21 Millennium Pharmaceuticals, Inc. Pyridobenzazépines et méthodes d'inhibition de la progression mitotique
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها

Also Published As

Publication number Publication date
HK1134672A1 (en) 2010-05-07
ATE556076T1 (de) 2012-05-15
KR20110113210A (ko) 2011-10-14
PL2497772T3 (pl) 2015-05-29
TWI401255B (zh) 2013-07-11
DK2497772T3 (en) 2015-01-19
SI2086981T1 (sl) 2012-12-31
US20150166545A1 (en) 2015-06-18
CR10782A (es) 2009-06-24
US20210214361A1 (en) 2021-07-15
AU2007322046B2 (en) 2012-04-05
EP2944639A1 (fr) 2015-11-18
PH12012502057B1 (en) 2018-10-24
NO20091864L (no) 2009-06-15
US8026246B2 (en) 2011-09-27
CN101547924A (zh) 2009-09-30
NZ577042A (en) 2012-03-30
EA015779B1 (ru) 2011-12-30
RS53788B1 (sr) 2015-06-30
BRPI0718803B8 (pt) 2021-05-25
NZ611898A (en) 2015-01-30
CA2669680C (fr) 2012-04-10
CL2007003244A1 (es) 2008-04-04
MX343391B (es) 2016-11-04
NZ597252A (en) 2013-06-28
EP2497772A1 (fr) 2012-09-12
CA2669680A1 (fr) 2008-05-29
US11958855B2 (en) 2024-04-16
BRPI0718803A2 (pt) 2013-12-03
HK1217699A1 (en) 2017-01-20
TW200829589A (en) 2008-07-16
EP2086981A1 (fr) 2009-08-12
US9765076B2 (en) 2017-09-19
MX348568B (es) 2017-06-20
ZA200903279B (en) 2010-07-28
MY153243A (en) 2015-01-29
AU2007322046A1 (en) 2008-05-29
ES2528793T3 (es) 2015-02-12
US20080167292A1 (en) 2008-07-10
US20240400567A1 (en) 2024-12-05
CY1112828T1 (el) 2016-02-10
BRPI0718803B1 (pt) 2020-11-17
NO343338B1 (no) 2019-02-04
US10836766B2 (en) 2020-11-17
HRP20150047T1 (en) 2015-03-13
US20190031662A1 (en) 2019-01-31
UA94129C2 (ru) 2011-04-11
CN103483343B (zh) 2016-06-01
HK1175778A1 (en) 2013-07-12
JP2010510215A (ja) 2010-04-02
HRP20120490T1 (hr) 2012-07-31
US20110312942A1 (en) 2011-12-22
JP5452811B2 (ja) 2014-03-26
US9988384B2 (en) 2018-06-05
EP2497772B1 (fr) 2014-10-29
ES2537451T3 (es) 2015-06-08
EP2497773A1 (fr) 2012-09-12
EP2086981B1 (fr) 2012-05-02
PH12012502057A1 (en) 2015-09-14
IL198690A0 (en) 2010-02-17
JP2014055166A (ja) 2014-03-27
ES2384123T3 (es) 2012-06-29
PL2086981T3 (pl) 2012-09-28
EP2497773B1 (fr) 2015-02-25
DK2086981T3 (da) 2012-08-06
RS52313B (sr) 2012-12-31
AR064246A1 (es) 2009-03-25
US20110312943A1 (en) 2011-12-22
KR20090091173A (ko) 2009-08-26
JP5102839B2 (ja) 2012-12-19
EP2944639B1 (fr) 2017-01-04
PT2497772E (pt) 2015-02-05
JP2012006965A (ja) 2012-01-12
SI2497772T1 (sl) 2015-03-31
KR101110458B1 (ko) 2012-03-13
MX2009004670A (es) 2009-05-15
PT2086981E (pt) 2012-06-20
WO2008063525A1 (fr) 2008-05-29
KR101342014B1 (ko) 2013-12-19
SG10201503350TA (en) 2015-06-29
HK1175777A1 (en) 2013-07-12
CR20140544A (es) 2015-01-12
CN103483343A (zh) 2014-01-01
GEP20125459B (en) 2012-03-26
EA200970486A1 (ru) 2009-10-30
CN101547924B (zh) 2013-09-25
SG176443A1 (en) 2011-12-29
CR20140154A (es) 2014-07-23

Similar Documents

Publication Publication Date Title
TNSN07305A1 (fr) Agonistes de pyy et leurs utilisations
MA31574B1 (fr) Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf
MA30166B1 (fr) Imidazoles substitues et leur utilisation comme pesticides.
MA30781B1 (fr) Inhibiteur de kinase
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
MA33275B1 (fr) Inhibiteurs de la replication du virus de l'immunodeficience humaine
MA29688B1 (fr) Formulation d'un inhibiteur de l'agregation plaquettaire thienopyridine
TN2011000454A1 (fr) Derives de benzofurannyle utilises comme inhibiteurs de glucokinase
PH12012502057A1 (en) Compounds for inhibiting mitotic progression
MA32104B1 (fr) Dérivés d'oxime en tant qu'inhibiteurs de hsp90
MA40225B1 (fr) Composés dihydroisoquinolinone substitués
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA32135B1 (fr) Inhibiteurs de pim kinase et leurs procedes d'utilisation
MA31433B1 (fr) Inhibiteurs de la p70 s6 kinase
MA29160B1 (fr) Derives de triazole substitues, servant d'antagonistes d'ocytocine
WO2006123113A3 (fr) Composes chimiques
MA32468B1 (fr) Derives de thiophene ou de thiazole et leur utilisation comme inhibiteurs de pi3k
MA32904B1 (fr) Composes de purine
MA31741B1 (fr) Derives fongicides de 2-alkylthio-2-quinolinyloxy- acetamide
TN2009000428A1 (fr) Derives de sulfonylamides destines au traitement d'une croissance cellulaire anormale
MA33730B1 (fr) Procédés de synthèse pour des composés spiro-oxindoles
TNSN08444A1 (en) Bicyclic derivatives as cetp inhibitors
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
MA30351B1 (fr) Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif